CYBIN
Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, United Kingdom and Ireland. The Company is focused on progressing Psychedelics to Therapeutics™ by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders.
CYBIN
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2019-01-01
Address:
Toronto, Ontario, Canada
Country:
Canada
Website Url:
http://www.cybin.com
Total Employee:
51+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
124.28 M CAD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics Font Awesome Global Site Tag
Similar Organizations
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Day One Biopharmaceuticals
Day One Biopharmaceuticals is a biotechnology company that focuses on developing new cancer therapies for patients of all ages.
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2020-12-14 | Adelia Therapeutics | Adelia Therapeutics acquired by Cybin | 20.16 M CAD |
Investors List
Bail Capital
Bail Capital investment in Series B - Cybin
Life Sciences Partners
Life Sciences Partners investment in Series B - Cybin
RA Capital Management
RA Capital Management investment in Series B - Cybin
Subversive Capital
Subversive Capital investment in Series B - Cybin
Noetic Fund
Noetic Fund investment in Series B - Cybin
Kearny Venture Partners
Kearny Venture Partners investment in Series B - Cybin
Janus Henderson Investors
Janus Henderson Investors investment in Series B - Cybin
Innovating Capital
Innovating Capital investment in Seed Round - Cybin
Key Employee Changes
| Date | New article |
|---|---|
| 2021-10-01 | Cybin Announces Appointment of Dr. Amir Inamdar as Chief Medical Officer for European Operations and Dr. Geoff Varty as the Head of Research and Development |
Official Site Inspections
http://www.cybin.com Semrush global rank: 1.98 M Semrush visits lastest month: 10.8 K
- Host name: 77.141.27.34.bc.googleusercontent.com
- IP address: 34.27.141.77
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Cybin"
Cybin - Crunchbase Company Profile & Funding
Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need …See details»
Cybin - Wikipedia
Cybin IRL is a Canadian pharmaceutical company that is developing psychedelic drugs as medicines. [1] [2] [3]The company's drug candidates include psilocybin (CYB001 ...See details»
Cybin Inc - LinkedIn
Exciting News from Cybin Inc!We are proud to announce that CenExel iResearch Atlanta is participating in Cybin's Strategic Partnership Agreement (SPA) program, supporting the Phase 3 development ...See details»
Cybin - Investor Relations
4 days ago Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people …See details»
Cybin Corporation - Psychedelic Science Review
Cybin Corporation. Cybin Corp is a Canadian biotechnology company founded in 2019. Originally embracing both pharmaceutical and nutraceutical fungi-based products, Cybin is now solely …See details»
Cybin Company Profile - Office Locations, Competitors, Revenue
Oct 29, 2024 Cybin formerly known as (Clarmin Explorations) is a biopharmaceutical company that focuses on developing psychedelic-based therapeutics. It offers drug development, …See details»
Cybin - Overview, News & Similar companies | ZoomInfo.com
Cybin is a leading ethical biotechnology company, working with a network of world-class partners and internationally recognized scientists, on a mission to create safe and effective therapeutics …See details»
Cybin Inc. (CYBN) Company Profile & Facts - Yahoo Finance
Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline …See details»
Cybin: Revenue, Worth, Valuation & Competitors 2025
Cybin is a Biotech related company founded in 2019 and based in Toronto with 75 employees an estimated revenue of $11.3M, and. It has 13 competitors including MindMed , Compass and …See details»
Our Team – Cybin
Prior to his current role at Cybin, Dr. Kelman was the Director of Training of the UCLA Prevention Center of Excellence in the Semel Institute for Neuroscience and Human Behavior. Dr. Kelman has published manuscripts on behavioral …See details»
Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and ...
TORONTO--(BUSINESS WIRE)-- Cybin Inc. (NYSE American:CYBN) (Cboe Canada CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed …See details»
Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based ...
4 days ago “This is an exciting time for Cybin as we focus on the execution of our Phase 3 CYB003 pivotal program,” said Doug Drysdale, Chief Executive Officer of Cybin. “Thermo …See details»
Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based ...
4 days ago Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the ... “Thermo Fisher, which offers leading Contract Development and Manufacturing Organization (CDMO) …See details»
Cybin Partners With Thermo Fisher for Phase 3 Depression Drug ...
3 days ago “This is an exciting time for Cybin as we focus on the execution of our Phase 3 CYB003 pivotal program,” said Doug Drysdale, Chief Executive Officer of Cybin. “Thermo …See details»
Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based ...
3 days ago TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry platform …See details»
Cybin - Investors - Governance - Board of Directors
At Cybin, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting …See details»
Partnerships - Cybin
Cybin has partnered with Clinilabs Drug Development Corporation, a global, full-service contract research organization with deep expertise in central nervous system drug development, to …See details»
Cybin Reports First Quarter Fiscal Year 2025 Financial Results and ...
Jun 30, 2024 TORONTO--(BUSINESS WIRE)-- Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage breakthrough neuropsychiatry …See details»
Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and ...
Dec 31, 2024 TORONTO--(BUSINESS WIRE)-- Cybin Inc. (NYSE American:CYBN) (Cboe Canada CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage breakthrough …See details»
Cybin - Cybin Partners with Osmind to Accelerate Commercial …
Apr 21, 2025 - Cybin will leverage Osmind's 800-clinic network, point-of-care software, and real-world data to support the commercial preparation for its clinical-stage pipeline - - Osmind is a …See details»